AP, December 18, 2022: Patients with ALS (also called Lou Gehrig’s disease) celebrated when FDA approved Relyvrio in 2022. But it costs $158k despite combining two old ingredients, the benefits are unclear, and the effective ingredient may be the one sold by Amazon for $1/day. Important research is underway to find out if the ingredient available on Amazon is equally or more effective, says Dr. Diana Zuckerman of National Center for Health Research.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Lasik Patients Should Be Warned of Complications, F.D.A. Draft Says
New York Times, December 7, 2022: FDA says many Lasik surgery patients develop double vision, dry eyes, difficulty driving at night and some have persistent eye pain. Diana Zuckerman says these FDA warnings should be required.
Read More »A Tiny Lab Finds Danger on Drugstore Shelves While the FDA Lags Behind
Bloomberg News, November 9, 2022: Valisure is a small lab that found carcinogens in Zantac, sunscreen, shampoo, sanitizers, and other products. NCHR asks: Why isn’t FDA doing these routine impurity tests? Too cozy with industry?
Read More »A Special Report: Can Breast Implants Cause Chronic Disease?
HealthCentral, October 25, 2022: This excellent review from HealthCentral.com quotes breast implant patients, NCHR and other experts responding to new FDA warnings and troubling research. We explain the research evidence of risks of breast implant illness and lymphoma and point out the misleading denials of risk by plastic surgeons.
Read More »FDA approves first ALS drug in 5 years after pleas from patients
Washington Post, September 29, 2022: FDA approves new ALS drug for Lou Gehrig’s disease despite NCHR and other experts’ criticisms that the drug’s effectiveness is questionable and FDA evidence standards should be higher.
Read More »